Imugene Limited’s (ASX:IMU) (OTCMKTS:IUGNF) Leslie Chong tells Proactive's Andrew Scott she's delighted with what the interim data has revealed in their ongoing randomised Phase 2 study of HER-Vaxx in gastric cancer. It's shown positive overall survival with a Hazard Ratio of 0.418. The median overall survival for patients receiving HER-Vaxx plus chemotherapy was 14.2 months, compared to 8.8 months in patients treated with chemotherapy alone. Chong says they're now assessing how best to take development of the drug forward.